title: The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the "Rete Ematologica Lombarda".
abstract: 5-Azacytidine is an effective therapy in high risk MDS and oligoblastic AML. This "real life" analysis was made on 185 patients treated with 5-azacytidine in 10 centers afferent to REL ("Rete Ematologica Lombarda"), a network in Lombardia region. The aim was to assess the influence of disease and comorbidity risk assessments on the survival. The results confirm the utility of 5-azacitidine in prolonging OS regardless of advanced age and the presence of comorbidities. They also encourage an early treatment since patients with IPSS-R High risk MDS have better outcome with respect to Very High risk ones. According to the IPSS cytogenetic risk, there was no difference in the outcome between Intermediate and High risk patients. Nevertheless, a poorer cytogenetic risk, according to the IPSS-R cytogenetic stratification, negatively influenced the outcome.
authors: Hematology, AO Niguarda Ca' Granda, Milan, Italy. Electronic address: alfredo.molteni@ospedaleniguarda.it.
authors: Alfredo
authors: A
authors: Molteni
authors: Hematology, AO Niguarda Ca' Granda, Milan, Italy.
authors: Marta
authors: M
authors: Riva
authors: Hematology, Ospedale San Gerardo, Monza, Italy.
authors: Lorenza
authors: L
authors: Borin
authors: Hematology, Ospedale San Raffaele, Milan, Italy.
authors: Massimo
authors: M
authors: Bernardi
authors: Hematology, Spedali Civili, Brescia, Italy.
authors: Anna Maria
authors: AM
authors: Pelizzari
authors: Hematology, Ospedale Maggiore Policlinico, Milan, Italy.
authors: Alessandra
authors: A
authors: Freyrie
authors: Hematology, Policlinico San Matteo, Pavia, Italy.
authors: Matteo
authors: M
authors: Della Porta
authors: Bio-statistics, AO Niguarda Ca' Granda, Milan, Italy.
authors: Michele
authors: M
authors: Nichelatti
authors: Hematology, AO Niguarda Ca' Granda, Milan, Italy.
authors: Emanuele
authors: E
authors: Ravano
authors: Hematology, Ospedale Papa Giovanni XXIII, Bergamo, Italy.
authors: Giulia
authors: G
authors: Quaresmini
authors: Transfusion and Hematology, AO "Treviglio-Caravaggio", Treviglio, Italy.
authors: Jacopo
authors: J
authors: Mariotti
authors: Hematology, Ospedale di Circolo e Fondazione Macchi, Varese, Italy.
authors: Domenica
authors: D
authors: Caramazza
authors: Hematology, Policlinico San Matteo, Pavia, Italy.
authors: Marta
authors: M
authors: Ubezio
authors: Hematology, Ospedale Maggiore Policlinico, Milan, Italy.
authors: Simona
authors: S
authors: Guarco
authors: Hematology, Istituto Europeo di Oncologia, Milan, Italy.
authors: Federica
authors: F
authors: Gigli
authors: Hematology, AO Niguarda Ca' Granda, Milan, Italy.
authors: Rosa
authors: R
authors: Greco
authors: Hematology, AO Niguarda Ca' Granda, Milan, Italy.
authors: Roberto
authors: R
authors: Cairoli
authors: Rete Ematologica Lombarda, Italy.
authors: Enrica
authors: E
authors: Morra
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use*; D015897:Comorbidity; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D012372:ROC Curve; D012189:Retrospective Studies; D012307:Risk Factors; D055815:Young Adult
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine
keywords: 5-Azacytidine; High risk myelodysplastic syndromes; Oligoblastic acute myeloid leukemia; Prognostic indices